Gene therapy for Wiskott-Aldrich syndrome: rescue of T-cell signaling and amelioration of colitis upon transplantation of retrovirally transduced hematopoietic stem cells in mice.
暂无分享,去创建一个
F. Alt | C. Klein | S. Snapper | T. Takenawa | R. Mulligan | D. Nguyen | A. Bhan | H. Miki | A. Mizoguchi | Ching-Hui Liu | F. Rosen
[1] A. Nienhuis,et al. Correction of the murine Wiskott-Aldrich syndrome phenotype by hematopoietic stem cell transplantation. , 2002, Blood.
[2] Sheila M. Thomas,et al. N-WASP deficiency reveals distinct pathways for cell surface projections and microbial actin-based motility , 2001, Nature Cell Biology.
[3] D. Nelson,et al. Somatic mosaicism in Wiskott–Aldrich syndrome suggests in vivo reversion by a DNA slippage mechanism , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[4] M. Yamada,et al. Spontaneous In Vivo Reversion of an Inherited Mutation in the Wiskott-Aldrich Syndrome1 , 2001, The Journal of Immunology.
[5] J. V. Stone,et al. Impact of donor type on outcome of bone marrow transplantation for Wiskott-Aldrich syndrome: collaborative study of the International Bone Marrow Transplant Registry and the National Marrow Donor Program. , 2001, Blood.
[6] K. Schwarz,et al. The interaction between Cdc42 and WASP is required for SDF-1-induced T-lymphocyte chemotaxis. , 2001, Blood.
[7] R. Buckley. Primary immunodeficiency diseases due to defects in lymphocytes. , 2000, The New England journal of medicine.
[8] W. Lim,et al. Integration of multiple signals through cooperative regulation of the N-WASP-Arp2/3 complex. , 2000, Science.
[9] M. Kirschner,et al. Mechanism of N-Wasp Activation by Cdc42 and Phosphatidylinositol 4,5-Bisphosphate , 2000, The Journal of cell biology.
[10] C. Klein,et al. Expression of Bcl-XL Restores Cell Survival, but Not Proliferation and Effector Differentiation, in Cd28-Deficient T Lymphocytes , 2000, The Journal of experimental medicine.
[11] C. Klein,et al. Comparative Analysis of Genetically Modified Dendritic Cells and Tumor Cells as Therapeutic Cancer Vaccines , 2000, The Journal of experimental medicine.
[12] F. Deist,et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. , 2000, Science.
[13] Michael K. Rosen,et al. Autoinhibition and activation mechanisms of the Wiskott–Aldrich syndrome protein , 2000, Nature.
[14] S. Tsuboi,et al. Expression of human Wiskott–Aldrich syndrome protein in patients’ cells leads to partial correction of a phenotypic abnormality of cell surface glycoproteins , 2000, Gene Therapy.
[15] K. Siminovitch,et al. Antigen Receptor–Induced Activation and Cytoskeletal Rearrangement Are Impaired in Wiskott-Aldrich Syndrome Protein–Deficient Lymphocytes , 1999, The Journal of experimental medicine.
[16] F. Facchetti,et al. Retrovirus-mediated WASP gene transfer corrects defective actin polymerization in B cell lines from Wiskott–Aldrich syndrome patients carrying ‘null’ mutations , 1999, Gene Therapy.
[17] M. Kirschner,et al. The Interaction between N-WASP and the Arp2/3 Complex Links Cdc42-Dependent Signals to Actin Assembly , 1999, Cell.
[18] S. Snapper,et al. The Wiskott-Aldrich syndrome protein (WASP): roles in signaling and cytoskeletal organization. , 1999, Annual review of immunology.
[19] Shiro Suetsugu,et al. WAVE, a novel WASP‐family protein involved in actin reorganization induced by Rac , 1998, The EMBO journal.
[20] C. Saxe,et al. SCAR, a WASP-related Protein, Isolated as a Suppressor of Receptor Defects in Late Dictyostelium Development , 1998, The Journal of cell biology.
[21] R. Badolato,et al. Monocytes from Wiskott-Aldrich patients display reduced chemotaxis and lack of cell polarization in response to monocyte chemoattractant protein-1 and formyl-methionyl-leucyl-phenylalanine. , 1998, Journal of immunology.
[22] Philip R. Cohen,et al. Wiskott-Aldrich syndrome protein-deficient mice reveal a role for WASP in T but not B cell activation. , 1998, Immunity.
[23] Dunn,et al. Chemotaxis of macrophages is abolished in the Wiskott‐Aldrich syndrome , 1998, British journal of haematology.
[24] Yoshimi Takai,et al. Induction of filopodium formation by a WASP-related actin-depolymerizing protein N-WASP , 1998, Nature.
[25] M. Gallego,et al. Defective actin reorganization and polymerization of Wiskott-Aldrich T cells in response to CD3-mediated stimulation. , 1997, Blood.
[26] R. Mulligan,et al. A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[27] K. Miura,et al. N‐WASP, a novel actin‐depolymerizing protein, regulates the cortical cytoskeletal rearrangement in a PIP2‐dependent manner downstream of tyrosine kinases. , 1996, The EMBO journal.
[28] A. Fischer,et al. Bone marrow transplantation in 26 patients with Wiskott-Aldrich syndrome from a single center. , 1996, The Journal of pediatrics.
[29] T. Kirchhausen,et al. Direct interaction of the Wiskott-Aldrich syndrome protein with the GTPase Cdc42. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[30] U. Francke,et al. Wiskott–Aldrich Syndrome Protein, a Novel Effector for the GTPase CDC42Hs, Is Implicated in Actin Polymerization , 1996, Cell.
[31] F. Rosen,et al. Nonrandom inactivation of the X chromosome in early lineage hematopoietic cells in carriers of Wiskott-Aldrich syndrome. , 1995, Blood.
[32] K. Sullivan,et al. A multiinstitutional survey of the Wiskott-Aldrich syndrome. , 1994, The Journal of pediatrics.
[33] U. Francke,et al. Isolation of a novel gene mutated in Wiskott-Aldrich syndrome. , 1994, Cell.
[34] C. Terhorst,et al. T cells of patients with the Wiskott-Aldrich syndrome have a restricted defect in proliferative responses. , 1993, Journal of immunology.
[35] R. Mulligan,et al. The basic science of gene therapy. , 1993, Science.
[36] E. Remold-O’Donnell,et al. T cell lines characterize events in the pathogenesis of the Wiskott- Aldrich syndrome , 1992, The Journal of experimental medicine.
[37] K. Siminovitch,et al. X-chromosome inactivation in the Wiskott-Aldrich syndrome: a marker for detection of the carrier state and identification of cell lineages expressing the gene defect. , 1989, Genomics.
[38] B. Vogelstein,et al. Carrier detection in the Wiskott Aldrich syndrome , 1988 .
[39] M. Chang,et al. Wiskott-Aldrich syndrome and inflammatory bowel disease. , 1988, Annals of allergy.
[40] J. Harley,et al. ALLELIC EXCLUSION OF GLUCOSE-6-PHOSPHATE DEHYDROGENASE IN PLATELETS AND T LYMPHOCYTES FROM A WISKOTT-ALDRICH SYNDROME CARRIER , 1980, The Lancet.
[41] J. Belli,et al. Complete correction of the Wiskott-Aldrich syndrome by allogeneic bone-marrow transplantation. , 1978, The New England journal of medicine.
[42] Aldrich Ra,et al. Pedigree demonstrating a sex-linked recessive condition characterized by draining ears, eczematoid dermatitis and bloody diarrhea. , 1954 .
[43] D. C. Campbell,et al. Pedigree demonstrating a sex-linked recessive condition characterized by draining ears, eczematoid dermatitis and bloody diarrhea. , 1954, Pediatrics.